Indication
Refractory Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type
2 clinical trials
2 products
1 drug
Clinical trial
Phase Ib Trial of Tegavivint in Patients With Relapsed/Refractory C-MYC Overexpressing Large B-Cell LymphomaStatus: Recruiting, Estimated PCD: 2027-03-05
Drug
TegavivintClinical trial
Phase 1/Expansion Study of Tazemetostat Plus Belinostat for the Treatment of Relapsed or Refractory LymphomaStatus: Recruiting, Estimated PCD: 2025-03-01
Product
BelinostatProduct
Tazemetostat